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Abstract
Background: As dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has
been implicated in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain,
and the development of neurofibrillary tangles, we examined the contribution of this gene to the
susceptibility for AD.
Methods: We examined genetic variations of DYRK1A by genotyping haplotype tagging SNPs
(htSNPs) (rs11701483, rs2835740, rs1137600, rs2835761, rs2835762, rs2154545 and rs8132976)
in a group of 634 Spanish AD cases and 733 controls.
Results: There were no differences in the genotypic, allelic or haplotypic distributions between
cases and controls in the overall analysis or after stratification by APOE ε4 allele.
Conclusion: Our negative findings in the Spanish population argue against the hypothesis that
DYRK1A genetic variations are causally related to AD risk. Still, additional studies using different
sets of patients and control subjects deserve further attention, since supporting evidence for
association between DYRK1A gene and AD risk in the Japanese population exists.
Background
Abnormal tau hyperphosphorylation has been suggested
as being one of the central events in the development of
neurofibrillary tangles (NFTs), which are one of the char-
acteristic neuropathological lesions found in Alzheimer's
disease (AD) brains [1]. Dual-specificity tyrosine phos-
phorylation-regulated kinase 1A (DYRK1A) phosphor-
ylates tau in vitro at the Thr212 residue [2], which is
hyperphosphorylated in AD brains, and a significant
increase in the amount of phosphor-Thr212-tau is also
found in the brains of transgenic mice that overexpress
human DYRK1A [3]. In addition, transgenic mice bearing
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a triple tau mutation and expressing hyperphosphor-
ylated tau in neurons of the hippocampus and neocortex
show increased expression of DYRK1A in individual neu-
rons in the same regions [4]. Moreover, DYRK1A accumu-
lates in NFTs in brains of subjects with sporadic AD and in
subjects with trisomy of chromosome 21 and Down syn-
drome (DS) [5]. The increase dosage of DYRK1A in DS
brain due to trisomy of chromosome 21 correlates to an
increase in three microtubule-binding domain repeats-tau
level [6], which on abnormal hyperphosphorylation and
aggregation of tau results in neurofibrillary degeneration
[7]. All this data postulates a role for DYRK1A as an inter-
esting genetic target for association analysis of AD.
Although genetic markers of the DYRK1A region were not
found associated to AD in recent genome-wide associa-
tion studies [8-11], Kimura et al. [12] scanned througt
chromosome 21 to assess genetic associations with late-
onset AD and found that DYRK1A showed the highest sig-
nificant association with AD risk in the Japanese popula-
tion. In addition, these authors suggested that DYRK1A
could be a key molecule bridging between β-amyloid pro-
duction and tau phosphorylation in AD [12]. In this
report we sought to replicate this genetic association in
the Spanish population.
Methods
The study included 634 AD patients (65% women; mean
age at study 75.9 years; SD 8.0; range 61-109 years; mean
age at onset 72.8 years; SD 7.9; range 60-108 years) who
met NINCDS/ADRDA criteria for probable AD [13]. All
AD cases were defined as sporadic because their family
history did not mention any first-degree relative with
dementia. AD patients were recruited from the Depart-
ments of Neurology of University Hospital "Marqués de
Valdecilla" (Santander, Spain), and Hospital "La Paz"
(Madrid, Spain). The large majority of patients were living
in the community and had been referred by their general
practitioner; few had been admitted from hospital wards
or nursing home facilities. Control subjects were 733
unrelated individuals (65% women; mean age 78.7 years;
SD 9.4; range 60-104 years) randomly selected from nurs-
ing homes. These subjects had complete neurologic and
medical examinations that showed that they were free of
significant illness and had Mini Mental State Examination
scores of 28 or more (corrected for age), which were veri-
fied by at least one subsequent annual following-up
assessment. The controls arose from the same base popu-
lation as the cases. The AD and control samples were Cau-
casians originating from a limited geographical area in
northern Spain (Santander) and from the central area of
Spain (Madrid).
Blood samples were taken after written informed consent
had been obtained from the subjects or their representa-
tives. The study was approved by the ethical committees
of the University Hospital "Marqués de Valdecilla" and
the Hospital "La Paz". Genotyping of DYRK1A
(rs11701483, rs2835740, rs1137600, rs2835761,
rs2835762, rs2154545 and rs8132976) polymorphism
was performed by a Taq-Man single-nucleotide-polymor-
phism assay (Applied Biosystems, Warrington, Cheshire,
UK) and an ABI PRISM 7000 or 7900HT sequence detec-
tion systems (Applied Biosystems). We used data from the
HapMap project http://www.hapmap.org to select the 7
htSNPs capturing 86% of DYRK1A genetic variability in
Caucasians. SNPs were chosen among those with minor
allele frequencies ≥ 5% using Haploview v3.2 software
http://www.broad.mit.edu/mpg/haploview with an r2
threshold of 0.8. The location of SNPs in DYRK1A gene
used in the present study is described in Figure 1. APOE
genotyping was performed by amplification of the 4th
exon of the APOE gene by PCR with biotinylated primers,
followed by reverse hybridization on nitrocellulose strips,
using the INNO-LIPA ApoE assay (Innogenetics NV,
Ghent, Belgium), or by HhaI restriction analysis.
Hardy-Weinberg equilibrium (HWE) was calculated for
the 7 htSNPs genotypes in the control population using
Pearson's χ2 statistics. We assessed pairwise linkage dise-
quilibrium (LD) between the 7 htSNPs by D' and r2 statis-
tics. Haplotype reconstruction and their frequencies in
cases and controls were estimated by an expectation-max-
imization algorithm. Pearson's χ2  statistics were per-
formed to compare allele distribution of the patients and
control for each htSNP. Haplotype frequencies were also
assessed using Pearson's χ2 using Haploview 3.32 software
Genomic structure and relative location of studied haplotype  tagging SNPs (indicated by grey boxes) in the DYRK1A gene Figure 1
Genomic structure and relative location of studied 
haplotype tagging SNPs (indicated by grey boxes) in 
the DYRK1A gene. Lines represent the introns between 
exons (black boxes). Pairwise linkage disequilibrium (LD) pat-
terns between the 7 htSNPs formed one haplotype block 
(numbers in box represent D' values, and the intensity of the 
color is proportional to the strength of the LD).BMC Medical Genetics 2009, 10:129 http://www.biomedcentral.com/1471-2350/10/129
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http://www.broad.mit.edu/mpg/haploview. Rare haplo-
types (total frequency < 0.05) were excluded from the
analysis.
Results
In control groups, no deviations from Hardy-Weinberg
equilibrium were found for any of the 7 htSNPs. As shown
in Table 1, the distribution of the allele and genotype fre-
quencies of the DYRK1A htSNPs did not differ signifi-
cantly between either un-stratified or APOE-stratified AD
and control groups. Figure 1 shows the pattern of pair
wise LD, measured in terms of D' coefficient, between the
7 chosen htSNPs. One block was found consisting of SNPs
rs11701483, rs2835740, rs1137600, rs2835761,
rs2835762 and rs2154545. When we estimated the haplo-
type frequencies in this haplotype block, we found that
the haplotype distribution did not differ significantly
between AD cases and controls (Table 2). There were no
major differences in allele, genotype or haplotype fre-
quencies of DYRK1A polymorphisms in our total sample
associated to either age or gender subgroups (data not
shown).
Discussion
In a series of 374 Japanese AD patients and 375 popula-
tion-based controls, Kimura et al. [12] studied eight tag-
ging SNPs (rs8126696, rs2251085, rs2835740,
rs10470178, rs11701810, rs1024294, rs2835773 and
rs2835774) located from 30 kb upstream of exon 1 to
exon 13, observing a three times increased AD risk for car-
riers of the DYRK1A rs2835740 CC genotype (OR = 2.99,
95% CI = 1.72-5.19, p = 0.001), and haplotype analysis
Table 1: Distribution of DYRK1A polymorphisms in patients and controls stratified by APOE ε4 allele
DYRK1A polymorphism APOE ε4 allele noncarriers APOE ε4 allele carriers Total sample
Patients Controls Patients Controls Patients Controls
rs11701483  AA 226 (0.78) 486 (0.79) 273 (0.83) 85 (0.74) 499 (0.81) 571 (0.79)
AG 58 (0.20) 119 (0.20) 54 (0.16) 27 (0.24) 112 (0.18) 146 (0.20)
GG 6 (0.02) 7 (0.01) 3 (0.01) 2 (0.02) 9 (0.01) 9 (0.01)
Total 290 612 330 114 620 726
Allele frequency A/G 0.88/0.12 0.89/0.11 0.91/0.09 0.86/0.14 0.89/0.11 0.89/0.11
rs2835740  TT 187 (0.65) 366 (0.62) 217 (0.66) 74 (0.66) 404 (0.66) 440 (0.62)
TC 86 (0.30) 206 (0.35) 90 (0.28) 31 (0.28) 176 (0.29) 237 (0.34)
CC 13 (0.05) 24 (0.04) 19 (0.06) 7 (0.06) 32 (0.05) 31 (0.04)
Total 286 596 326 112 612 708
Allele frequency T/C 0.80/0.20 0.79/0.21 0.80/0.20 0.80/0.20 0.80/0.20 0.79/0.21
rs1137600  AA 124 (0.44) 276 (0.46) 164 (0.53) 50 (0.45) 288 (0.49) 326 (0.46)
AG 124 (0.44) 261 (0.43) 107 (0.35) 46 (0.42) 231 (0.39) 307 (0.43)
GG 32 (0.12) 69 (0.11) 37 (0.12) 14 (0.13) 69 (0.12) 83 (0.12)
Total 280 606 308 110 588 716
Allele frequency A/G 0.62/0.38 0.67/0.33 0.71/0.29 0.66/0.34 0.69/0.31 0.67/0.33
rs2835761  CC 203 (0.70) 422 (0.69) 232 (0.72) 84 (0.75) 435 (0.71) 506 (0.70)
CT 82 (0.29) 176 (0.29) 85 (0.26) 27 (0.24) 167 (0.27) 203 (0.28)
TT 4 (0.01) 11 (0.02) 6 (0.02) 1 (0.01) 10 (0.02) 12 (0.02)
Total 289 609 323 112 612 721
Allele frequency C/T 0.84/0.16 0.84/0.16 0.85/0.15 0.87/0.13 0.85/0.15 0.84/0.16
rs2835762  CC 216 (0.81) 467 (0.78) 243 (0.77) 82 (0.73) 459 (0.79) 549 (0.78)
CT 49 (0.18) 119 (0.20) 69 (0.22) 27 (0.24) 118 (0.20) 146 (0.21)
TT 3 (0.01) 9 (0.02) 4 (0.01) 3 (0.03) 7(0.01) 12 (0.01)
Total 268 595 316 112 584 707
Allele frequency C/T 0.90/0.10 0.88/0.12 0.88/0.12 0.85/0.15 0.89/0.11 0.88/0.12
rs2154545  GG 105 (0.37) 218 (0.36) 141 (0.43) 43 (0.38) 246 (0.40) 261 (0.36)
GA 136 (0.47) 280 (0.46) 135 (0.42) 49 (0.44) 271 (0.44) 329 (0.46)
AA 45 (0.16) 108 (0.18) 50 (0.15) 20 (0.18) 95 (0.16) 128 (0.18)
Total 286 606 326 112 612 718
Allele frequency G/A 0.60/0.40 0.59/0.41 0.64/0.36 0.60/0.40 0.62/0.38 0.59/0.41
rs8132976  AA 95 (0.34) 194 (0.33) 93 (0.29) 33 (0.30) 188 (0.31) 227 (0.32)
AC 122 (0.43) 285 (0.48) 138 (0.43) 48 (0.43) 260 (0.43) 333 (0.47)
CC 66 (0.23) 116 (0.19) 91 (0.28) 30 (0.27) 157 (0.26) 146 (0.21)
Total 283 595 322 111 605 706
Allele frequency A/C 0.55/0.45 0.57/0.43 0.50/0.50 0.51/0.49 0.53/0.47 0.56/0.44
Figures in parentheses indicate frequencies; p-values > 0.05 for all allelic and genotypic comparisons; p-values were not corrected for multiple 
comparisons.BMC Medical Genetics 2009, 10:129 http://www.biomedcentral.com/1471-2350/10/129
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indicated that two haplotypes had significantly different
frequencies between AD and controls. These authors
showed that the expression of DYRK1A mRNA was ele-
vated in the hippocampus of AD patients, coinciding with
another report of increased DYRK1A immunoreactivity in
the frontal cortex, entorhinal cortex and hippocampus of
AD patients [4]. All the tagging SNPs analyzed in our
study are located in a single block that does not cover the
whole gene (captures 86% of DYRK1A genetic variability),
but is the same haplotype block as described by Kimura et
al. in their Japanese cohort. It could have been a great
interest to identify possible DYRK1A genetic association
using tagging SNPs located in haplotype blocks flanking
the block illustrated in Figure 1; however, our main objec-
tive was to study the most strongly associated SNP
rs2835740 (intron 3) of the original paper suggesting
DYRK1A as a putative gene causing AD [12], and, in addi-
tion, we genotyped other SNPs in intron 3 (rs11701483,
rs1137600 and rs2835761), intron 4 (rs2835762) and
intron 10 (rs2154545 and rs8132976). In contrast with
the findings of Kimura et al., we did not find any genetic
association. Our failure to replicate the main finding of
Kimura et al. could be caused by several factors. The pos-
sibility of a type 2 error (false-negative) must be taken in
account, but we had enough power (98%) to detect an
odds ratio of 1.5 at disease allele frequencies of approxi-
mately 0.15. Another possibility is genetic heterogeneity
between our sample sets and those of the original study.
While DYRK1A rs2835740 revealed evidence for associa-
tion in Japanese samples, this SNP was not associated
with AD in our Caucasian sample, and independent repli-
cation studies are needed in this gene to verify or refute
the finding here and to extend it to other ethnic groups.
Conclusion
Our negative findings in the Spanish population argue
against the hypothesis that DYRK1A genetic variations are
causally related to AD risk. Still, additional studies using
different sets of patients and control subjects deserve fur-
ther attention, since supporting evidence for association
between DYRK1A gene and AD risk in the Japanese popu-
lation exists.
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